Boston Scientific Corporation
Boston Scientific Corporation’s Free Cash Flow Growth at a glance
Boston Scientific Corporation reports free cash flow growth of 55.3% for Dec 2024. The prior period recorded 86.3% (Dec 2023). Year over year the metric moved −31 pts (−35.9%). The rolling three-period average stands at 37%. Data last refreshed Dec 18, 2025, 4:52 PM.
Latest reading
55.3% · Dec 2024
YoY movement
−31 pts (−35.9%)
Rolling average
37%
Current Free Cash Flow Growth
55.3%
−31 pts
−35.9%
Rolling average
37%
Latest Value
55.3%
Dec 2024
YoY Change
−31 pts
Absolute
YoY Change %
−35.9%
Rate of change
3-Period Avg
37%
Smoothed
Narrative signal
Boston Scientific Corporation’s free cash flow growth stands at 55.3% for Dec 2024. Year-over-year, the metric shifted by −31 pts, translating into a −35.9% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How free cash flow growth shapes Boston Scientific Corporation's story
As of Dec 2024, Boston Scientific Corporation reports free cash flow growth of 55.3%. Gauge reinvestment strength and capital return capacity using free cash flow growth over multiple reporting periods.
Cash flow versus earnings
Free cash flow growth can diverge from earnings due to working capital and capex swings. Track both to confirm quality.
Capital allocation insights
Rising free cash flow enables dividends, buybacks, and debt reduction—key levers for shareholder value.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
61.3%
Operating Margin
15.7%
Net Profit Margin
11.1%
Return on Equity
8.5%
Return on Assets
4.7%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Boston Scientific Corporation (BSX) FAQs
Answers tailored to Boston Scientific Corporation’s free cash flow growth profile using the latest Financial Modeling Prep data.
What is Boston Scientific Corporation's current free cash flow growth?
As of Dec 2024, Boston Scientific Corporation reports free cash flow growth of 55.3%. This reading reflects the latest filings and price data for BSX.
How is Boston Scientific Corporation's free cash flow growth trending year over year?
Year-over-year, the figure shifts by −31 pts (−35.9%). Pair this context with revenue growth and free cash flow signals to gauge momentum for BSX.
Why does free cash flow growth matter for Boston Scientific Corporation?
Free cash flow growth measures how quickly operating cash surplus expands compared with the prior period. For Boston Scientific Corporation, operating within Healthcare — Medical - Devices, tracking this metric helps benchmark management's execution against close competitors.
Is Boston Scientific Corporation's free cash flow growth above its recent average?
Boston Scientific Corporation's rolling three-period average sits at 37%. Comparing the latest reading of 55.3% to that baseline highlights whether momentum is building or fading for BSX.
How frequently is Boston Scientific Corporation's free cash flow growth refreshed?
Data for BSX was last refreshed on Dec 18, 2025, 4:52 PM and updates automatically every 24 hours, keeping your valuation inputs current.